Arndt Stahler

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Dominik Paul Modest, Ingrid Ricard, Volker Heinemann et al. · Annals of Oncology · 2016 · 334 citations · Full text

Clonal hematopoiesis is associated with improved survival in patients with metastatic colorectal cancer from the FIRE-3 trial

Christopher Maximilian Arends, Savvina Dimitriou, Arndt Stahler et al. · Blood · 2021 · 52 citations · Full text

Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study—XELAVIRI (AIO KRK0110)

Dominik Paul Modest, Ludwig Fischer von Weikersthal, Thomas Decker et al. · Journal of Clinical Oncology · 2018 · 47 citations

Influence of m<scp>RNA</scp> expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5‐<scp>FU/LV</scp> plus irinotecan or irinotecan plus oxaliplatin as first‐line treatment (<scp>FIRE</scp> 1‐trial)

Arndt Stahler, Volker Heinemann, Clemens Gießen-Jung et al. · International Journal of Cancer · 2015 · 37 citations · Full text

The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancer

Alexander J. Ohnmacht, Arndt Stahler, Sebastian Stintzing et al. · Nature Communications · 2023 · 34 citations · Full text